Renal Cell Carcinoma | Unmet Need | Metastatic Renal Cell Carcinoma | US/EU | 2018

The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor Opdivo, which was approved for this indication as monotherapy in 2015 and in combination with the CTLA-4 inhibitor Yervoy in 2018, has revolutionized clinical practice. Although existing treatment options aim to improve PFS, significant need remains for well-tolerated therapies that can extend the OS and PFS of patients with advanced or metastatic renal cell carcinoma.


  • What are the treatment drivers that are most likely to influence a therapy’s uptake for advanced or metastatic renal cell carcinoma?
  • How do current therapies for advanced or metastatic renal cell carcinoma perform on key attributes?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across key clinical attributes and price when considering hypothetical new treatment options for advanced or metastatic renal cell carcinoma?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Login to access report

launch Related Market Assessment Reports